Alexion Pharmaceuticals, Inc. said the US Patent and Trademark Office (USPTO) issued three patents for its expensive rare disease treatment Soliris.
Soliris treats two rare blood disorders and has a US list price of about $480,000 per year, according to Reuters.
Alexion said the three new patents “are directed to the composition of matter of eculizumab (Soliris), pharmaceutical formulations of eculizumab, and methods of treating paroxysmal nocturnal hemoglobinuria (PNH) with eculizumab, respectively, and which will expire in 2027.”
Alexion CEO Ludwig Hantson said: “Alexion is the leader in complement biology and has invested decades of ground-breaking research and development in Soliris.
“We continue to strengthen our patent portfolio around this unique complement inhibitor.
“These new patents work in concert with other patents and regulatory exclusivities to protect Soliris in all indications.”
Alexion said it is pursuing corresponding patent applications in other regions and countries, including Europe and Japan.
Alexion also said it is pursuing patent applications for pending additional indications of Soliris, such as for the treatment of refractory generalized myasthenia gravis (gMG).
According to Alexion, Soliris works “by inhibiting terminal complement, a part of the immune system that, when activated in an uncontrolled manner, plays a role in serious diseases like paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).”